Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD)

被引：0

作者：

Weidinger, Stephan ^{[1
]}

Blauvelt, Andrew ^{[2
]}

Papp, Kim ^{[3
,4
]}

Reich, Adam ^{[5
]}

Lee, Chih-Hung ^{[6
]}

Worm, Margitta ^{[7
]}

Lynde, Charles ^{[8
,9
]}

Kataoka, Yoko ^{[10
]}

Foley, Peter ^{[11
]}

Weber, Christine ^{[12
]}

Solente, Anne-Catherine ^{[12
]}

Adelman, Samuel ^{[13
]}

Davey, Sonya ^{[13
]}

Wong, Wanling ^{[14
]}

Rynkiewicz, Natalie ^{[13
]}

Yen, Karl ^{[15
]}

O'Malley, John T. ^{[13
]}

Bernigaud, Charlotte ^{[12
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Dermatol & Allergy, Kiel, Germany

[2] Blauvelt Consulting LLC, Lake Oswego, OR USA

[3] Alliance Clin Trials & Prob Med Res, Waterloo, ON, Canada

[4] Univ Toronto, Toronto, ON, Canada

[5] Univ Rzeszow, Dept Dermatol, Rzeszow, Poland

[6] Kaohsiung Chang Gung Mem Hosp, Dept Dermatol, Kaohsiung, Taiwan

[7] Univ Med Ctr Berlin, Dept Dermatol & Allergol, Berlin, Germany

[8] Univ Toronto, Markham, ON, Canada

[9] Prob Med Res, Markham, ON, Canada

[10] Osaka Habikino Med Ctr, Habikino, Japan

[11] Skin Hlth Inst, Carlton, Vic, Australia

[12] Sanofi, Paris, France

[13] Sanofi, Cambridge, MA USA

[14] Sanofi, Bridgewater, NJ USA

[15] Sanofi, Rotkreuz, Switzerland

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷

关键词：

amlitelimab; atopic dermatitis; STREAM-AD; clinical response; efficacy; safety;

D O I：

10.1093/bjd/ljae266.039

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

661

引用

页数：2